Skip to search formSkip to main contentSkip to account menu

VS-6063

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

defactinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Merck , Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer Release
  • 2018
  • Corpus ID: 53992862
DARMSTADT, Germany & NEW YORK & BOSTON--(BUSINESS WIRE)--Merck, Pfizer and Verastem announced today that they have entered into… 
2016
2016
Abstract B031: FAK/PYK2 inhibition enhances antitumor efficacy of anti-PD-1 and anti-4-1BB antibodies
Although durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to… 
2016
2016
T-03 Exposure-Response Analyses to Assess Lack of QT Prolongation by VS-6063 in Healthy Subjects or in Patients with non-Hematologic Malignancies
Methods: In Study B0761001 (n=46), the safety, pharmacokinetics (PK) and pharmacodynamics of single and multiple-doses of VS-6063… 
2015
2015
Abstract 974: FAK inhibitors VS-6063 and VS-4718 target cancer stem cells: Implications for TNBC sequential and combination therapies
2014
2014
Abstract 4797: VS-6063 (defactinib) targets cancer stem cells directly and through inhibition of tumor-associated macrophages and cytokine production
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase which mediates integrin and growth factor receptor signaling to… 
2014
2014
Abstract 3908: Focal adhesion kinase (FAK) inhibitor VS-6063 (defactinib) preferentially targets cancer stem cells in triple negative breast cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Triple negative breast cancer (TNBC) is defined… 
2013
2013
Abstract A39: FAK inhibitors VS-6063 and VS-4718 preferentially target ovarian cancer stem cells
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that orchestrates cell signaling through integrins and growth…